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Ischemia–reperfusion treatment: 
opportunities point to modulation 
of the inflammatory response
KMA Rouschop1 and JC Leemans2
Ischemia–reperfusion injury is the leading cause of acute renal 
failure and determinant of renal-transplant outcome. Although many 
experimental studies show decreased injury and preserved renal 
function after dampening of the inflammatory response, surprisingly 
little progress has been made in the development of novel therapies.
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Renal ischemia–reperfusion injury
Renal injury due to ischemia–reperfusion 
(I/R) occurs when kidneys undergo a tem-
porary deprivation of blood followed by 
the return of the blood supply. I/R injury 
is a major clinical problem with increasing 
incidence and signiﬁcant morbidity and 
mortality and accounts for a major eco-
nomic burden to the community. It is the 
most common cause of acute renal failure 
after renal transplantation, shock, sepsis, 
and renal artery stenosis. I/R injury fol-
lowing transplantation is associated with 
delayed graft function and is one of the 
major risk factors for acute renal trans-
plant rejection and the development of 
chronic allograft nephropathy. For patients 
in shock, acute tubular necrosis due to I/R 
injury is associated with a mortality rate of 
approximately 50%, and little progress has 
been made in the design of eﬀective thera-
pies in the past 40 years. Treatment of I/R 
injury is still only supportive. Therefore, it 
is essential to develop preventive or thera-
peutic interventions and gain knowledge 
of the underlying mechanisms to prevent 
or reduce renal tissue injury following I/R. 
Sandovici et al.1 (this issue) studied the 
eﬀects of interleukin (IL)-13 on renal I/R 
injury using systemic gene therapy, and 
their results may allow better treatment of 
ischemic renal failure in the future.
Renal I/R injury is associated with a 
large number of pathophysiological altera-
tions resulting in the destruction of tissue. 
Ischemic acute renal injury is a self-heal-
ing disease, but only to a limited extent; 
exceeding this extent results in irreversible 
loss of renal function. I/R injury is associ-
ated with tubulointerstitial inﬂammation, 
which is characterized by an inﬂux of leu-
kocytes early after reperfusion. Attraction 
of leukocytes to the postischemic tissue is 
regulated by chemotactic factors, includ-
ing complement components such as C3a 
and C5a and a number of chemokines/
cytokines, such as tumor necrosis factor-α 
(TNF-α), IL-1β, IL-8 (murine homologue 
is keratinocyte-derived chemokine (KC)), 
interferon-γ  monocyte chemotactic 
protein 1 (MCP-1), and macrophage 
inﬂammatory protein (MIP)-2.
Initially, heparan sulfate proteoglycans, 
including syndecans, glypicans, and 
CD44, create a local concentration gradi-
ent of chemotactic factors, leading to the 
recruitment of leukocytes. Endothelial 
cells express many heparan sulfate pro-
teoglycans, suggesting a crucial role for 
heparan sulfate during inﬂammation.2 
Moreover, inﬂammatory cytokines such 
as IL-1, TNF-α, and interferon-γ induce 
expression of adhesion molecules on 
endothelial cells, which are pivotal to leu-
kocyte migration.
Non-activated circulating leukocytes do 
not adhere well to endothelium, but adhe-
sion is increased by chemokine activation; 
strong adhesion is mediated by integrins 
(such as LFA-1 and VLA-4) that interact 
with counter-receptors on the endothe-
lium (intercellular adhesion molecule-1 
and vascular cell adhesion molecule-1, 
respectively). After integrin-mediated 
ﬁrm attachment is established, leukocytes 
migrate through the endothelial-cell layer 
and basement membrane to enter the tissue 
(as reviewed by Roitt et al.3) (Figure 1).
Detection of ischemia–reperfusion injury
As oxygen and nutrients are lacking during 
a period of ischemia, cells will be unable 
to generate adenosine triphosphate (ATP) 
through oxidative phosphorylation. ATP 
depletion will eventually lead to necrosis 
and apoptosis of renal cells and the subse-
quent release of endogenous danger mol-
ecules. These endogenous components 
trigger an intense inﬂammatory response 
mediated by Toll-like receptor (TLR) 
pathways, a family consisting of at least 12 
members. Endothelial chemokine upregu-
lation is mediated by TLR-4, and blockade 
of TLR-4 attenuated damage after renal 
I/R injury.4 TLR-2 deﬁciency or antisense 
treatment decreased neutrophil inﬂux by 
more than 75% and subsequently protected 
the kidneys from I/R injury.5
Cytokines and chemokines
After the initial recognition of I/R damage, 
an inﬂammatory response is initiated, and 
leukocytes are activated and directed to the 
site of inﬂammation. This is mediated by a 
cocktail of cytokines and chemokines that 
negatively inﬂuence renal outcome. San-
dovici et al.1 demonstrate that manipulat-
ing this cocktail by providing more IL-13 
systemically can dampen the inﬂammatory 
response and protect the kidney from injury 
and dysfunction. This observation and that 
of others6 suggest that in addition to strat-
egies focusing on the removal of a single 
proinﬂammatory cytokine, chemokine, or 
receptor (such as IL-1, -6, -8, -12, or -16, 
TNF-α, MIP-2, stromal cell–derived 
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factor-1 (SDF-1), growth–regulated protein-
α (GRO-α), or one of many more7), tipping 
the balance of this cytokine mix in a more 
anti-inﬂammatory direction is a potential 
new approach to ameliorating I/R injury.
Therefore, anti-inﬂammatory cytokines 
can be excellent candidates for therapy 
of I/R injury, as they can reverse the pro-
inﬂammatory process. Surprisingly few 
studies have focused on this approach to 
limiting renal I/R injury.
IL-13 is a potent T-helper type 2 cytokine 
that is capable of suppressing acute inﬂam-
matory responses and displays cytoprotec-
tive properties. IL-13 suppresses production 
of proinflammatory cytokines such as 
TNF-α, MCP-1, MIP-2, IL-8 (Sandovici 
et al.1), IL-1, IL-6, and MIP-1α (reviewed 
by Cavaillon8), all considered to play a role 
in the exaggerated inﬂammatory response 
following I/R. Hence, decreased E-selec-
tin expression was observed. Impairment 
of the influx of neutrophils and macro-
phages into the postischemic tissue (50% 
reduction) resulted in preservation of renal 
function. Sandovici et al.1 used an adeno-
viral gene transfer approach to reach high 
plasma levels of IL-13 for up to 4 days. This 
gene therapy approach bypasses approaches 
with recombinant proteins, which are com-
plicated by their short half-life. In this way 
the requirement for repetitive administra-
tion of IL-13 protein is prevented. Another 
advantage of the gene therapy approach of 
Sandovici et al.1 is that the period of expres-
sion of an adenovirus-encoded transgene 
is relatively short in contrast to long-term 
gene therapy approaches. This makes it a 
highly suitable method to treat renal I/R 
injury, which is often transient and revers-
ible. The short-term expression of the 
therapeutic gene also allows for a certain 
degree of regulation of administration of 
the therapeutic gene product, in contrast 
to long-term gene therapy approaches. 
On the other hand, this system might be 
less controllable than injections, and IL-13 
plasma levels may be diﬃcult to predict. 
As the authors have indications that the 
eﬀect of IL-13 is mediated by direct action 
on renal cells, local, rather than systemic, 
delivery of IL-13 might be a better approach 
to attenuate renal I/R injury, as it avoids del-
eterious side eﬀects often associated with 
systemic therapy.
The results of Sandovici et al.1 provide 
strong evidence that IL-13 gene therapy is a 
powerful therapeutic approach to enhance 
IL-13 levels, resulting in a reduction in 
renal I/R injury. Although most current 
gene transfer technologies are experimen-
tal and have not proven very successful in 
clinical trials, gene therapy may represent 
an attractive approach in inhibiting I/R 
injury, organ dysfunction, and rejection 
in renal-transplant recipients. The cadav-
eric kidney can be targeted relatively easily 
with the adenoviral IL-13 vector, reducing 
potentially deleterious systemic side eﬀects. 
This would be highly important, as IL-13 
plays a major role in tissue ﬁbrosis and vari-
ous diseases, including cancer, asthma, and 
allergy. Although the ﬁndings of Sandovici 
et al.1 are promising, it would be crucial in 
the future to demonstrate that IL-13 gene 
therapy can also ameliorate ischemic acute 
renal failure when applied early in the 
clinical course of injury instead of before 
the onset of injury. As the maximal IL-13 
expression is achieved several days after 
adenoviral administration, the beneﬁcial 
effect of this protein on early ischemic 
events may be limited. Additionally, as we 
consider I/R an inﬂammatory response, 
intravenous administration of adenovi-
ruses might have additional eﬀects on the 
already activated immune system. Great 
caution should be taken in the treatment 
of I/R patients with gene therapy.
The study of Sandovici et al.1 is a clear 
example of how alteration of the inﬂam-
matory response is capable of reducing 
renal I/R injury. In the past decades, 
numerous studies have been performed 
that show this eﬀect on diﬀerent levels 
within the proinflammatory cascade, 
giving ample opportunity for the devel-
opment of novel treatment regimes.
Opportunities
The fact that inﬂammation contributes to 
the maximal deterioration of the kidney 
after I/R-induced injury, coupled now 


















Figure 1 | Schematic overview of events after I/R injury with the according treatment 
opportunities. During ischemia, tubular epithelial cells (TECs) will be deprived of oxygen, adenosine 
triphosphate may be depleted, and cells will become necrotic. Ischemia followed by reperfusion 
will generate reactive oxygen species affecting the TECs. Injured TECs and TECs recognizing necrotic 
remnants will generate a cocktail of cytokines and chemokines. Subsequently this will lead to rolling, 
arrest, and extravasation of neutrophils into the postischemic tissue. Treatment opportunities are 
depicted next to the overview. ICAM-1, intercellular adhesion molecule-1; IL, interleukin; GRO-α, 
growth–regulated protein-α; MIP-2, macrophage inflammatory protein-2; SDF-1, stromal cell–
derived factor-1; TLR, Toll-like receptor; TNF-α, tumor necrosis factor-α.
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evidence that modulation of the immune 
response is beneﬁcial, suggests that future 
therapies can be based on this modula-
tion (Figure 1). As continuing research 
unravels the plethora of mechanisms at 
play, the number of targets and potential 
treatment opportunities will increase. 
Strategies that target each step of the 
recruitment, activation, and modula-
tion of the inﬂammatory response are 
possible. Among the opportunities for 
salutary intervention in renal I/R injury 
as highlighted by the study of Sandovici 
et al.1 is a strategy that alters the balance 
between pro- and anti-inflammatory 
aspects of the response to such injury. A 
cautionary note must be sounded, as such 
modulation of the immune system may 
have unintended and long-term conse-
quences. IL-13 alterations may interfere 
with the normal clearance of pathogens, 
since IL-13 potently inhibits the normal 
T-helper type 1 response to invading 
pathogens. Nevertheless, as I/R injury 
is the leading cause of acute renal failure 
and determinant of the outcome after 
renal transplantation, every opportunity 
should be investigated in the pursuit of 
novel treatments.
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Nephrogenic systemic fibrosis:  
the story unfolds
D Prchal1, DT Holmes2 and A Levin1
The purpose of this Commentary is to briefly summarize the current 
knowledge of nephrogenic systemic fibrosis in order to promote better 
understanding of the complexity of chronic kidney disease and its 
associated conditions.
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Although recognized as a clinical entity in 
1997, nephrogenic systemic ﬁbrosis (NSF) 
was not reported in the literature until 
2000.1 First termed nephrogenic ﬁbros-
ing dermopathy, the condition was char-
acterized by extensive cutaneous ﬁbrosis 
mimicking scleroderma but with notable 
sparing of the face and neck, absence of 
scleroderma-associated autoantibodies, 
and absence of local inﬂammation (his-
tologically). Over the past 7 years it has 
become clear that nephrogenic ﬁbrosing 
dermopathy does not exclusively aﬀect 
the skin. Evidence of sclerosis has been 
identiﬁed in lungs, heart, liver, and mus-
cles, and therefore the term NSF better 
describes the systemic nature of the con-
dition.2 Because of the devastating nature 
of the disease, in less than one decade it 
has gone from a state of obscurity to one 
of common parlance among nephrolo-
gists, dermatologists, and radiologists. 
Notwithstanding, the pathobiology of 
NSF remains incompletely understood.
Current state
The link to gadolinium-containing con-
trast agents (GCCAs), ﬁrst established in 
2006,3 has led several regulatory bodies to 
issue practice-altering recommendations. 
In its communiqué dated 23 May 2007, 
the United States Food and Drug Admin-
istration advises health-care professionals 
to avoid using GCCAs in persons at risk 
for the development of NSF, to evaluate 
patients for renal dysfunction, to not 
exceed the recommended GCCA dose in 
product labeling, and to consider prompt 
hemodialysis after administration of a 
GCCA.4 The American College of Radi-
ology has issued a similar recommenda-
tion. In this era of increasing attention 
to patient safety and rapid disclosure of 
medical error, these recommendations 
have necessarily emphasized the need for 
a highly conservative approach to the use 
of gadolinium.
It is important to maintain an appro-
priate perspective, understand this con-
dition, and deal with it in a systematic 
evidence-based manner. In particular we 
need to ask a series of questions to move 
the inquiry from phenomenology to epi-
demiology to pathobiology expeditiously 
so that we can understand and prevent 
the occurrence of NSF. With ongoing 
publication of progressively sophisti-
cated analyses of cases, case series, and 
databases, we should be able to accom-
plish this in the near future (Figure 1). 
In a manner akin to that of the recent 
recognition, and subsequent diminution, 
of the incidence and severity of erythro-
poietin-associated pure red-cell aplasia, 
the nephrology community again has a 
unique opportunity to understand and 
prevent a rare condition. We must hypoth-
esize what key factors create the ‘perfect 
storm’ from which the disease phenotype 
